南昌治疗儿童癫痫病医院哪家好南昌市治疗神经病医院排名,南昌如何忧郁症治疗,南昌市中医神经病地址,南昌市第十二医院专业吗贵不贵,南昌市治疗的精神病医院,南昌看焦虑症去那个医院比较好,南昌哪家医院的神经官能好

WASHINGTON, May 20 (Xinhua) -- Two U.S. astronauts conducted the first of four spacewalks for space shuttle Endeavour's STS-134 mission on Friday morning, the U.S. National Aeronautics and Space Administration (NASA) said.According to the U.S. space agency, Endeavour's mission specialists Andrew Feustel and Greg Chamitoff completed the six-hour, 19-minute spacewalk at 9:29 a.m. EDT (1329 GMT). They successfully installed antennas for the External Wireless Communication system, routing cables, setting up the antenna, installing handrails, and connecting power cables.Because of a carbon dioxide sensor failure in Chamitoff's spacesuit, flight controllers limited his spacewalk time to about six hours 20 minutes, 10 minutes less than the planned six hours and 30 minutes. There was no indication his suit's carbon dioxide levels would rise. However, they deferred tasks to remove a micrometeoroid debris shield to access and attach some of the connection points.This was the 245th spacewalk conducted by U.S. astronauts. It was Feustel's fourth spacewalk for a total time of 27 hours and 17 minutes, and Chamitoff's first.Endeavour lifted off on Monday morning from Kennedy Space Center in Florida, to deliver to the International Space Station a 2-billion-dollar, multinational particle detector known as the Alpha Magnetic Spectrometer (AMS).AMS, a particle physics detector, is designed to search for various types of unusual matter by measuring cosmic rays. Its experiments are designed to help researchers study the formation of the universe and search for evidence of dark matter, strange matter and antimatter.

BEIJING, Feb. 12 (Xinhua) -- China said late Saturday that members of the United Nations should work for a broadly-based consensus on the reform of the UN Security Council.Foreign Ministry spokesman Ma Zhaoxu made the remarks in response to a relevant question.Media reports had it that a recently-released declaration by some countries said most of UN member nations supported enlarging the council with new permanent and non-permanent members, and insisted tangible results be achieved in this regard during the Current Session of the UN General Assembly.Ma said China held that UN member nations should seek for a package of solutions for the reform, on the basis of broad and democratic consultation among member nations to accommodate interests and concerns of all parties.He said though some positive progress had been made since inter-government negotiations regarding the reform of the UN Security Council were launched, there were still serious differences within all parties over certain important issues about the reform.China advocated that the more differences the member countries had on the reform, the more necessary for UN member nations to enhance dialogue and consultation, he said."Experience has proven that presetting results for the reform or forcing premature reform plans will not only undermine the unity of UN member nations, but also harm the reform process, which will not be in line with any party's interests," he said.China is ready to maintain contact with all relevant parties, and make joint efforts with other member nations to push forward the reform in a way which can be conducive to safeguarding the overall interests of UN and the unity of the member nations, said Ma.

BEIJING, March 24 (Xinhuanet) -- A new study has found that Actos, a medicine treats onset diabetes, could also reduce the diabetes risk in people with prediabetes.The study, which was published Wednesday in New England Journal of Medicine, followed 602 prediabetics whose obesity, ethnicity, family history and other factors put them at high risk of developing diabetes.The research findings showed that Actos, generically known as pioglitazone, reduced the odds of developing Type 2 diabetes by 72 percent in people with prediabetes.Only 2.1 percent of those who took Actos developed diabetes each year over the three years of the study, compared with 7.6 percent of those who took a placebo.Lead author of the study Ralph DeFronzo said, "The 72 percent reduction is the largest decrease in the conversion rate of pre-diabetes to (Type 2) diabetes that has ever been demonstrated by any intervention, be it diet, exercise or medication."However, Actos can have significant side effects, including water retention, moderate weight gain, and increased risk of bone fractures.

BEIJING, Feb. 18 (Xinhua) -- Jia Qinglin, China's top political advisor, urged the municipality of Beijing to intensify efforts to promote the development of service and manufacturing industries.Jia, chairman of the National Committee of the Chinese People's Political Consultative Conference, made the remarks during his inspection tour in Beijing from Wednesday to Friday.During the tour, Jia visited factories, construction sites and communities to exchange views with officials and civilians. He also listened to a report from the Beijing municipal government.Beijing has taken the lead in optimizing its industrial structure as the output of its service industry accounts for 75 percent of the revenue from all sectors, according to official sources of the city.Jia encouraged Beijing to continue to promote its service sector by focusing on producer services and expanding the city's service businesses overseas.While visiting Beijing Benz Automotive Co., Ltd., Jia called for the strengthening of technological innovation in order to boost high-end equipment manufacturing.Beijing should turn itself into a center for national technological innovation to contribute to the country's economic development, Jia said.He also stressed the better protection of forest resources and the more efficient use of water to develop modern agriculture.

BRUSSELS, April 29 (Xinhua) -- As a 2004 European Union (EU) directive on herbal medicine is to be fully implemented on May 1, herbal medicinal products without a license will no longer be allowed in the EU market, the European Commission said in a press release Friday.The Traditional Herbal Medicinal Products Directive, adopted by the EU member states in 2004, introduced a so-called simplified registration procedure with a seven-year transition period for traditional herbal medicinal products to obtain a medicine license.As the transition period is to expire on Saturday, herbal medicinal products from home and abroad, most of which have been sold as food supplements for decades, need to be medically registered or authorized by EU governments in order to remain in the market after May 1.Instead of going through safety tests and clinical trials as regular chemical drugs, applicants are required by the directive to provide documents showing the herbal medicinal product is not harmful in the specified condition of use, as well as evidence that the product at least has a 30-year history of safe use, including 15 years in the EU.However, a wide range of eligibility and technical challenges along with prohibitive costs have so far prevented both local and outside herbal medicinal products from being granted the license.Only a small proportion of indigenous herbal medicinal products have been approved for registration while not a single Chinese or Indian traditional herbal medicinal products have been licensed.Lack of pan-European rules, EU member states had adopted different approaches to herbal medicine, thus creating a "state of anarchy" in the markets despite the fact that indigenous herbs had a 700-year history of use in Europe.Although the directive was intended to harmonize rules of member states and build a level-playing field across the EU, critics argued that the directive may fall short of the aim and create more chaos and uncertainties for the industry.DRAWBACKSThe directive has been under attack for being neither "adequate " nor "appropriate" due to its high registration cost for a single product and its lack of consideration about the Chinese and Indian traditional herbal medicine.Chris Dhaenens, a licensed herbalist in Belgium and a shareholder of a medium-sized herbal importing company doing business with China and ten European countries, said the directive was only appropriate for companies carrying a few products and who could afford the registration costs."It is simply inaccessible to most players distributing high- quality Chinese or Indian herbal products in Europe," he said, adding that the registration fee for a single product could be as high as 150,000 euros.The Alliance for Natural Health, a British-based group representing herbal practitioners, estimated the cost of obtaining a license at between 80,000 and 120,000 pounds (90,000 to 135,000 U.S. dollars) per herb.Dhaenens, who is also the president of the European Benefyt Foundation, a leading traditional medicine group in Europe, argued that the directive only tried to regulate herbal products instead of its practitioners and the whole herbal system, as well as fell short to take the Chinese and Indian traditional medicine into full consideration.Even the European Commission had admitted that the directive was not fit for the registration of Chinese and Indian medicine in an earlier exchange with the European Medicine Agency in Dec. 2008, Dhaenens revealed in an exclusive interview with Xinhua."But they had no money or time to work out an alternative, and so it was left to the member states," he said.